References
- Lin J. T., Bertino J. R. Trimetrexate: A second generation folate antagonist in clinical trial. J Clin Oncol 1987; 5: 2032–2040
- Baker B. R. Designs of Active-Site-Specific-Directed Irreversible Enzyme Inhibitors. Wiley, New York 1967
- Elslager E. F., Johnson J. L., Werberl L. M. Folate antagonists 20. Synthesis, antitumor, and antimalarial properties of trimetrexate and related 6-(phenylamino)-2,4-quinazoline-diamines. J Med Chem 1983; 26: 1753–1760
- Werbel L. M. Design and synthesis of lipophilic antifols and anticancer agents. Folate Antagonists as nerapeutic Agents, F. M. Sirotnak, J. J. Burchall, W. D. Ensminger, et al. Academic, San Diego 1984; 261–287
- Jackson R. C., Leopold W. R., Hamelehle K. L., Fry D. W. Preclinical studies with trimetrexate. A review of conclusions and unanswered questions. Semin Oncol 1988; 15: l–7
- Maroun J. Clinical response to trimetrexate as sole therapy for non-small cell lung cancer. Semin Oncol 1988; 15: 17–21
- Robert F. Trimetrexate as a single agent in patients with advanced head and neck cancer. Semin Oncol 1988; 15: 22–26
- Bertino J. R. Trimetrexate. Overall clinical results. Semin Oncol 1988; 15: 50–51
- Marsoni S., Hoth D., Salmon R., Leyland-Jones B., De Rosa M., Wittes R. E. Clinical drug development. An analysis of phase II trials, 1970–1985. Cancer Treat Rep 1987; 71: 71–80
- Benz C., Cadman E. Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. Cancer Res 1981; 41: 944–999
- Mulder J. H., Smink T., Van Putten L. M. 5-Fluorouracil and methotrexate combination chemotherapy. The effect of drug scheduling. Eur J Cancer Clin Oncol 1981; 17: 831–837
- Hudes G. R., Comis R. L. Phase 1 and 2 studies of trimetrexate administration in combination with fluorouracil to patients with metastatic cancer. Semin Oncol 1988; 15: 41–45